US EditionAstrazeneca: Berenberg, Positive with Data on Hypertension
Summary by Merca2.es
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Berenberg’s analysts are positive with the British pharmaceutical company AstraZeneca after assessing the latest data on Baxdostrat for hypertension. In a recent note they reiterate their recommendation to Buy and its target price of 142 pounds sterling based on positive data on blood pressure reduction with Baxdrostat: “We have increased our net present value (VAN) for Baxdrostat following the presentation of positive data in the ESC (adding 0.…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
